4507:TYO
Shionogi & Co Ltd
၂,၇၉၀.၀၀ JP¥
arrow_downward
-၀.၈၇%(-၂၄.၅၀) 1D
အောက် ၁၄, GMT+၉ ၁၅:၃၀:၀၀ · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4507...
Open
၂,၇၉၀ JP¥
High
၂,၈၀၀ JP¥
Low
၂,၇၆၂ JP¥
Mkt. cap
ဋေ ၂.၄၈ သိန်း
Avg. vol.
၃.၀၃ သန်း
Volume
၂.၂၆ သန်း
Dividend
၂.၅၄%
Quarterly dividend
၁၈ JP¥
Ex-dividend date
၂၀၂၆ စက် ၂၉
P/E ratio
၉.၀၁
52-wk high
၃,၇၅၈ JP¥
52-wk low
၂,၃၉၂ JP¥
EPS
၃၁၀ JP¥
Shares outstanding
၃၁.၄၅ ကုဋေ
No. of employees
၆ ထောင်
Open
၂,၇၉၀ JP¥
High
၂,၈၀၀ JP¥
Low
၂,၇၆၂ JP¥
Mkt. cap
ဋေ ၂.၄၈ သိန်း
Avg. vol.
၃.၀၃ သန်း
Volume
၂.၂၆ သန်း
Dividend
၂.၅၄%
Quarterly dividend
၁၈ JP¥
Ex-dividend date
၂၀၂၆ စက် ၂၉
P/E ratio
၉.၀၁
52-wk high
၃,၇၅၈ JP¥
52-wk low
၂,၃၉၂ JP¥
EPS
၃၁၀ JP¥
Shares outstanding
၃၁.၄၅ ကုဋေ
No. of employees
၆ ထောင်
News stories
From web sources and news partners
StockStory
·
ပြီးခဲ့သည့် ၈ မိနစ်
1 S&P 500 Stock with Competitive Advantages and 2 We Brush Off
MarketBeat
·
ပြီးခဲ့သည့် ၃၁ မိနစ်
X-Energy (NASDAQ:XE) Reaches New 12-Month Low - Time to Sell?
Investor's Business Daily
·
ပြီးခဲ့သည့် ၉ မိနစ်
Dow Futures Rise; ASML Earnings Beat, CPI Inflation Due
Seeking Alpha
·
ပြီးခဲ့သည့် ၂ နာရီ
Dow Jones Industrial Average Monitor Update - A Look At 30 U.S. Large-Caps
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
About Shionogi & Co Ltd